Stevenage, United Kingdom

Rachael Anne Ancliff

USPTO Granted Patents = 3 


Average Co-Inventor Count = 6.9

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2006-2009

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Rachael Anne Ancliff: Innovator in Inflammatory Disease Treatment

Introduction: Rachael Anne Ancliff, an accomplished inventor based in Stevenage, GB, has made significant contributions to the field of pharmaceutical innovations. With a total of three patents, she has specialized in developing novel compounds that exhibit therapeutic potential for treating inflammatory diseases.

Latest Patents: Among her latest innovations are two notable patents focused on morpholin-acetamide derivatives. These patents include compounds of formula (I), providing detailed processes for their preparation, formulations containing these compounds, and their therapeutic uses specifically aimed at the treatment of inflammatory diseases.

Career Highlights: Rachael is currently associated with Glaxo Group Limited, where she applies her expertise in drug development. Her work is pivotal in advancing medical treatments and enhancing patients' quality of life through innovative pharmaceutical solutions.

Collaborations: Throughout her career, Rachael has collaborated with esteemed colleagues, including Simon Teanby Hodgson and Xiao Qing Lewell. Their combined efforts contribute to breakthroughs in the pharmaceutical industry, underlining the importance of teamwork in driving innovation.

Conclusion: Rachael Anne Ancliff exemplifies the spirit of innovation in the pharmaceutical realm. Her patents not only reflect her commitment to addressing critical health issues but also highlight the collaborative efforts that propel advancements in medical research. With her contributions, Rachael continues to make a lasting impact in the treatment of inflammatory diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…